| Combination of | |
|---|---|
| Telmisartan | Angiotensin II receptor antagonist |
| Amlodipine | Calcium channel blocker |
| Clinical data | |
| Trade names | Twynsta, others |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Telmisartan/amlodipine, sold under the brand name Twynsta among others, is a fixed-dose combination medication used to treat high blood pressure. It is a combination of telmisartan, an angiotensin II receptor antagonist, and amlodipine, as the besilate, a calcium channel blocker. It is taken by mouth.
Common side effects include dizziness, swelling, and back pain. Severe side effects may include low blood pressure, kidney problems, electrolyte problems, and a heart attack. Use during pregnancy may harm the baby. Telmisartan works by blocking the effects of angiotensin II while amlodipine works by decreasing calcium ion entry into smooth muscle and heart muscle.
The combination was approved for medical use in the United States in 2009. The combination is on the World Health Organization's List of Essential Medicines. It is available as a generic medication.
References
- "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
- ^ "DailyMed - Telmisartan and Amlodipine tablet". DailyMed. Retrieved 30 October 2019.
- "Twynsta (telmisartan/amlodipine) tablets, for oral use Initial U.S. Approval: 2009". DailyMed. Retrieved 18 March 2023.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- "Telmisartan and Amlodipine (Professional Patient Advice)". Drugs.com. Retrieved 30 October 2019.
